The collaboration will see the integration of Optibrium’s StarDrop software as a central component of MSD’s global drug discovery infrastructure
CAMBRIDGE, UK, 10 November 2020: Optibrium™, a developer of software for drug discovery, today announced a collaboration with MSD tradename of Merck & Co., Inc, Kenilworth NJ USA. As part of the collaboration MSD has adopted Optibrium’s StarDrop™ software as a central component of their cheminformatics infrastructure.
The collaboration, between MSD and Optibrium will include integration of StarDrop with MSD’s in-house capabilities and the joint development of new tools, to improve cycle times, efficiency and productivity of the drug discovery process.
Dr Matthew Segall, Optibrium’s CEO, commented, “We are delighted to enter this collaboration to contribute to MSD’s world-leading cheminformatics infrastructure. We look forward to working together to advance new tools based around StarDrop to further refine our compound design platform.”
StarDrop is a complete package of fully integrated, elegant software for small molecule design, optimisation and data analysis. It supports researchers by quickly targeting high-quality chemistry in hit-to-lead and lead optimisation. StarDrop’s unique approach to multi-parameter optimisation combined with cutting-edge predictive modelling and generative chemistry capabilities helps to guide compound design decisions, and will enable MSD’s researchers to explore new optimisation strategies.